Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Circulating RNAs as predictive markers for the progression of type 2 diabetes.

Ghai V, Baxter D, Wu X, Kim TK, Kuusisto J, Laakso M, Connolly T, Li Y, Andrade-Gordon P, Wang K.

J Cell Mol Med. 2019 Apr;23(4):2753-2768. doi: 10.1111/jcmm.14182. Epub 2019 Feb 7.

2.

The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction.

Bode MF, Auriemma AC, Grover SP, Hisada Y, Rennie A, Bode WD, Vora R, Subramaniam S, Cooley B, Andrade-Gordon P, Antoniak S, Mackman N.

Thromb Res. 2018 Jul;167:128-134. doi: 10.1016/j.thromres.2018.05.015. Epub 2018 May 17.

PMID:
29843086
3.

Identification of novel biomarkers to monitor β-cell function and enable early detection of type 2 diabetes risk.

Belongie KJ, Ferrannini E, Johnson K, Andrade-Gordon P, Hansen MK, Petrie JR.

PLoS One. 2017 Aug 28;12(8):e0182932. doi: 10.1371/journal.pone.0182932. eCollection 2017.

4.

CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

Di Prospero NA, Artis E, Andrade-Gordon P, Johnson DL, Vaccaro N, Xi L, Rothenberg P.

Diabetes Obes Metab. 2014 Nov;16(11):1055-64. doi: 10.1111/dom.12309. Epub 2014 May 25.

PMID:
24798870
5.

Serine protease inhibition reduces post-ischemic granulocyte recruitment in mouse intestine.

Gobbetti T, Cenac N, Motta JP, Rolland C, Martin L, Andrade-Gordon P, Steinhoff M, Barocelli E, Vergnolle N.

Am J Pathol. 2012 Jan;180(1):141-52. doi: 10.1016/j.ajpath.2011.09.031. Epub 2011 Nov 7.

6.

Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.

Parry TJ, Huang Z, Chen C, Connelly MA, Perzborn E, Andrade-Gordon P, Damiano BP.

Blood Coagul Fibrinolysis. 2011 Dec;22(8):720-6. doi: 10.1097/MBC.0b013e32834cb30e.

PMID:
21986468
7.

Contribution of bone marrow-derived cells to the pro-inflammatory effects of protease-activated receptor-2 in colitis.

Hyun E, Andrade-Gordon P, Steinhoff M, Beck PL, Vergnolle N.

Inflamm Res. 2010 Sep;59(9):699-709. doi: 10.1007/s00011-010-0181-9. Epub 2010 Mar 26.

8.

Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.

Lu T, Markotan T, Ballentine SK, Giardino EC, Spurlino J, Crysler CS, Brown K, Maryanoff BE, Tomczuk BE, Damiano BP, Shukla U, End D, Andrade-Gordon P, Bone RF, Player MR.

J Med Chem. 2010 Feb 25;53(4):1843-56. doi: 10.1021/jm901802n. Erratum in: J Med Chem. 2010 Apr 22;53(8):3422. Crysler, Carl S [added].

PMID:
20102150
9.

Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor Xa.

Giardino EC, Haertlein BJ, de Garavilla L, Costanzo MJ, Damiano BP, Andrade-Gordon P, Maryanoff BE.

Blood Coagul Fibrinolysis. 2010 Mar;21(2):128-34. doi: 10.1097/MBC.0b013e3283358100.

PMID:
20010091
10.

Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation.

Maryanoff BE, de Garavilla L, Greco MN, Haertlein BJ, Wells GI, Andrade-Gordon P, Abraham WM.

Am J Respir Crit Care Med. 2010 Feb 1;181(3):247-53. doi: 10.1164/rccm.200904-0627OC. Epub 2009 Oct 29.

PMID:
19875688
11.

Thrombin receptor: An endogenous inhibitor of inflammatory pain, activating opioid pathways.

Martin L, Augé C, Boué J, Buresi MC, Chapman K, Asfaha S, Andrade-Gordon P, Steinhoff M, Cenac N, Dietrich G, Vergnolle N.

Pain. 2009 Nov;146(1-2):121-9. doi: 10.1016/j.pain.2009.07.016. Epub 2009 Aug 11.

PMID:
19674841
12.

Protective role for protease-activated receptor-2 against influenza virus pathogenesis via an IFN-gamma-dependent pathway.

Khoufache K, LeBouder F, Morello E, Laurent F, Riffault S, Andrade-Gordon P, Boullier S, Rousset P, Vergnolle N, Riteau B.

J Immunol. 2009 Jun 15;182(12):7795-802. doi: 10.4049/jimmunol.0803743.

13.

Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice.

Versteeg HH, Schaffner F, Kerver M, Ellies LG, Andrade-Gordon P, Mueller BM, Ruf W.

Cancer Res. 2008 Sep 1;68(17):7219-27. doi: 10.1158/0008-5472.CAN-08-0419.

14.

Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.

Gunnet JW, Wines P, Xiang M, Rybczynski P, Andrade-Gordon P, de Garavilla L, Parry TJ, Cheung WM, Minor L, Demarest KT, Maryanoff BE, Damiano BP.

Eur J Pharmacol. 2008 Aug 20;590(1-3):333-42. doi: 10.1016/j.ejphar.2008.06.010. Epub 2008 Jun 7.

PMID:
18599033
15.

Protease-activated receptor-2 activation: a major actor in intestinal inflammation.

Hyun E, Andrade-Gordon P, Steinhoff M, Vergnolle N.

Gut. 2008 Sep;57(9):1222-9. doi: 10.1136/gut.2008.150722. Epub 2008 May 6.

PMID:
18460552
16.

Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation.

Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, Chun J, Derian CK, Andrade-Gordon P, Rosen H, Ruf W.

Nature. 2008 Apr 3;452(7187):654-8. doi: 10.1038/nature06663. Epub 2008 Feb 27.

PMID:
18305483
17.

Mechanisms underlying the nociceptive and inflammatory responses induced by trypsin in the mouse paw.

Paszcuk AF, Quintão NL, Fernandes ES, Juliano L, Chapman K, Andrade-Gordon P, Campos MM, Vergnolle N, Calixto JB.

Eur J Pharmacol. 2008 Feb 26;581(1-2):204-15. Epub 2007 Nov 23.

PMID:
18083162
18.

Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy.

Pawlinski R, Tencati M, Hampton CR, Shishido T, Bullard TA, Casey LM, Andrade-Gordon P, Kotzsch M, Spring D, Luther T, Abe J, Pohlman TH, Verrier ED, Blaxall BC, Mackman N.

Circulation. 2007 Nov 13;116(20):2298-306. Epub 2007 Oct 29.

19.

Intrathecal administration of proteinase-activated receptor-2 agonists produces hyperalgesia by exciting the cell bodies of primary sensory neurons.

Alier KA, Endicott JA, Stemkowski PL, Cenac N, Cellars L, Chapman K, Andrade-Gordon P, Vergnolle N, Smith PA.

J Pharmacol Exp Ther. 2008 Jan;324(1):224-33. Epub 2007 Oct 5.

PMID:
17921188
20.

Proteinase-activated receptor-2 exerts protective and pathogenic cell type-specific effects in Alzheimer's disease.

Afkhami-Goli A, Noorbakhsh F, Keller AJ, Vergnolle N, Westaway D, Jhamandas JH, Andrade-Gordon P, Hollenberg MD, Arab H, Dyck RH, Power C.

J Immunol. 2007 Oct 15;179(8):5493-503.

21.

Mandatory role of proteinase-activated receptor 1 in experimental bladder inflammation.

Saban R, D'Andrea MR, Andrade-Gordon P, Derian CK, Dozmorov I, Ihnat MA, Hurst RE, Davis CA, Simpson C, Saban MR.

BMC Physiol. 2007 Mar 30;7:4.

22.

Regulatory network of inflammation downstream of proteinase-activated receptors.

Saban R, D'Andrea MR, Andrade-Gordon P, Derian CK, Dozmorov I, Ihnat MA, Hurst RE, Simpson C, Saban MR.

BMC Physiol. 2007 Mar 30;7:3.

23.

Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis.

Uusitalo-Jarvinen H, Kurokawa T, Mueller BM, Andrade-Gordon P, Friedlander M, Ruf W.

Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1456-62. Epub 2007 Mar 15.

PMID:
17363687
24.

Role for protease activity in visceral pain in irritable bowel syndrome.

Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N.

J Clin Invest. 2007 Mar;117(3):636-47. Epub 2007 Feb 15.

25.

Urotensin-II induces ear flushing in rats.

Qi JS, Schulingkamp R, Parry TJ, Colburn R, Stone D, Haertlein B, Minor LK, Andrade-Gordon P, Damiano BP.

Br J Pharmacol. 2007 Feb;150(4):415-23. Epub 2007 Jan 8.

26.

Proteinase-activated receptors, targets for kallikrein signaling.

Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, Blaber SI, Scarisbrick I, Andrade-Gordon P, Cottrell GS, Bunnett NW, Diamandis EP, Hollenberg MD.

J Biol Chem. 2006 Oct 27;281(43):32095-112. Epub 2006 Aug 2.

27.

A role for proteinase-activated receptor-1 in inflammatory bowel diseases.

Vergnolle N, Cellars L, Mencarelli A, Rizzo G, Swaminathan S, Beck P, Steinhoff M, Andrade-Gordon P, Bunnett NW, Hollenberg MD, Wallace JL, Cirino G, Fiorucci S.

J Clin Invest. 2006 Jul;116(7):2056. No abstract available.

28.

Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.

Gong Y, Barbay JK, Dyatkin AB, Miskowski TA, Kimball ES, Prouty SM, Fisher MC, Santulli RJ, Schneider CR, Wallace NH, Ballentine SA, Hageman WE, Masucci JA, Maryanoff BE, Damiano BP, Andrade-Gordon P, Hlasta DJ, Hornby PJ, He W.

J Med Chem. 2006 Jun 1;49(11):3402-11.

PMID:
16722660
29.

Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist.

Gunnet JW, Matthews JM, Maryanoff BE, de Garavilla L, Andrade-Gordon P, Damiano B, Hageman W, Look R, Stahle P, Streeter AJ, Wines PG, Demarest KT.

Clin Exp Pharmacol Physiol. 2006 Apr;33(4):320-6.

PMID:
16620295
30.

Protease-activated receptor-2 activation: a major role in the pathogenesis of Porphyromonas gingivalis infection.

Holzhausen M, Spolidorio LC, Ellen RP, Jobin MC, Steinhoff M, Andrade-Gordon P, Vergnolle N.

Am J Pathol. 2006 Apr;168(4):1189-99.

31.

Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.

Leger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L, Kuliopulos A.

Circulation. 2006 Mar 7;113(9):1244-54. Epub 2006 Feb 27.

PMID:
16505172
32.

Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.

Noorbakhsh F, Tsutsui S, Vergnolle N, Boven LA, Shariat N, Vodjgani M, Warren KG, Andrade-Gordon P, Hollenberg MD, Power C.

J Exp Med. 2006 Feb 20;203(2):425-35. Epub 2006 Feb 13.

33.

Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response.

Cenac N, Cellars L, Steinhoff M, Andrade-Gordon P, Hollenberg MD, Wallace JL, Fiorucci S, Vergnolle N.

Inflamm Bowel Dis. 2005 Sep;11(9):792-8.

PMID:
16116312
34.

A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis.

Hansen KK, Sherman PM, Cellars L, Andrade-Gordon P, Pan Z, Baruch A, Wallace JL, Hollenberg MD, Vergnolle N.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8363-8. Epub 2005 May 26.

35.

Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection.

Noorbakhsh F, Vergnolle N, McArthur JC, Silva C, Vodjgani M, Andrade-Gordon P, Hollenberg MD, Power C.

J Immunol. 2005 Jun 1;174(11):7320-9.

36.

In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.

Costanzo MJ, Almond HR Jr, Hecker LR, Schott MR, Yabut SC, Zhang HC, Andrade-Gordon P, Corcoran TW, Giardino EC, Kauffman JA, Lewis JM, de Garavilla L, Haertlein BJ, Maryanoff BE.

J Med Chem. 2005 Mar 24;48(6):1984-2008. Erratum in: J Med Chem. 2007 Nov 15;50(23):5868.

PMID:
15771442
37.

Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.

Zhang HC, Derian CK, McComsey DF, White KB, Ye H, Hecker LR, Li J, Addo MF, Croll D, Eckardt AJ, Smith CE, Li Q, Cheung WM, Conway BR, Emanuel S, Demarest KT, Andrade-Gordon P, Damiano BP, Maryanoff BE.

J Med Chem. 2005 Mar 24;48(6):1725-8.

PMID:
15771419
38.

Characterization of functional urotensin II receptors in human skeletal muscle myoblasts: comparison with angiotensin II receptors.

Qi JS, Minor LK, Smith C, Hu B, Yang J, Andrade-Gordon P, Damiano B.

Peptides. 2005 Apr;26(4):683-90. Epub 2005 Jan 1.

PMID:
15752584
39.

A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo.

de Garavilla L, Greco MN, Sukumar N, Chen ZW, Pineda AO, Mathews FS, Di Cera E, Giardino EC, Wells GI, Haertlein BJ, Kauffman JA, Corcoran TW, Derian CK, Eckardt AJ, Damiano BP, Andrade-Gordon P, Maryanoff BE.

J Biol Chem. 2005 May 6;280(18):18001-7. Epub 2005 Feb 28.

40.

A role for proteinase-activated receptor-1 in inflammatory bowel diseases.

Vergnolle N, Cellars L, Mencarelli A, Rizzo G, Swaminathan S, Beck P, Steinhoff M, Andrade-Gordon P, Bunnett NW, Hollenberg MD, Wallace JL, Cirino G, Fiorucci S.

J Clin Invest. 2004 Nov;114(10):1444-56. Retraction in: Vergnolle N, Cellars L, Mencarelli A, Rizzo G, Swaminathan S, Beck P, Steinhoff M, Andrade-Gordon P, Bunnett NW, Hollenberg MD, Wallace JL, Cirino G, Fiorucci S. J Clin Invest. 2006 Jul;116(7):2056.

41.

Protection against acute pancreatitis by activation of protease-activated receptor-2.

Sharma A, Tao X, Gopal A, Ligon B, Andrade-Gordon P, Steer ML, Perides G.

Am J Physiol Gastrointest Liver Physiol. 2005 Feb;288(2):G388-95. Epub 2004 Sep 30.

42.

Activation of proteinase-activated receptor-1 inhibits neurally evoked chloride secretion in the mouse colon in vitro.

Buresi MC, Vergnolle N, Sharkey KA, Keenan CM, Andrade-Gordon P, Cirino G, Cirillo D, Hollenberg MD, MacNaughton WK.

Am J Physiol Gastrointest Liver Physiol. 2005 Feb;288(2):G337-45. Epub 2004 Sep 2.

43.

Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1).

Maryanoff BE, Zhang HC, Andrade-Gordon P, Derian CK.

Curr Med Chem Cardiovasc Hematol Agents. 2003 Mar;1(1):13-36. Review.

PMID:
15317288
44.

High-throughput siRNA-based functional target validation.

Xin H, Bernal A, Amato FA, Pinhasov A, Kauffman J, Brenneman DE, Derian CK, Andrade-Gordon P, Plata-Salamán CR, Ilyin SE.

J Biomol Screen. 2004 Jun;9(4):286-93.

PMID:
15191645
45.

3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3.

Zhang HC, Ye H, Conway BR, Derian CK, Addo MF, Kuo GH, Hecker LR, Croll DR, Li J, Westover L, Xu JZ, Look R, Demarest KT, Andrade-Gordon P, Damiano BP, Maryanoff BE.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3245-50.

PMID:
15149684
46.

Mer receptor tyrosine kinase signaling participates in platelet function.

Chen C, Li Q, Darrow AL, Wang Y, Derian CK, Yang J, de Garavilla L, Andrade-Gordon P, Damiano BP.

Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):1118-23. Epub 2004 May 6.

PMID:
15130911
47.

Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates.

Matthews JM, Hoekstra WJ, Dyatkin AB, Hecker LR, Hlasta DJ, Poulter BL, Andrade-Gordon P, de Garavilla L, Demarest KT, Ericson E, Gunnet JW, Hageman W, Look R, Moore JB, Reynolds CH, Maryanoff BE.

Bioorg Med Chem Lett. 2004 Jun 7;14(11):2747-52.

PMID:
15125926
48.

Gene expression analysis for high throughput screening applications.

Pinhasov A, Mei J, Amaratunga D, Amato FA, Lu H, Kauffman J, Xin H, Brenneman DE, Johnson DL, Andrade-Gordon P, Ilyin SE.

Comb Chem High Throughput Screen. 2004 Mar;7(2):133-40.

PMID:
15032660
49.

Aza-bicyclic amino acid sulfonamides as alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.

Dyatkin AB, Hoekstra WJ, Kinney WA, Kontoyianni M, Santulli RJ, Kimball ES, Fisher MC, Prouty SM, Abraham WM, de Garavilla L, Andrade-Gordon P, Hlasta DJ, He W, Hornby PJ, Damiano BP, Maryanoff BE.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):591-6. Erratum in: Bioorg Med Chem Lett. 2004 May 3;14(9):2371.

PMID:
14741249
50.

Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia.

Pawlinski R, Pedersen B, Schabbauer G, Tencati M, Holscher T, Boisvert W, Andrade-Gordon P, Frank RD, Mackman N.

Blood. 2004 Feb 15;103(4):1342-7. Epub 2003 Oct 23.

Supplemental Content

Loading ...
Support Center